IGF-1 (insulin-like growth factor 1)

Reference ranges

Optimal ranges are tighter than standard lab ranges and reflect functional-medicine targets, not the populations they were derived from. Reference bands depend on sex, age, and circumstance — Juno's lab analysis layers your profile context onto the printed range when you paste a value.

Peptide relevance

Most directly affected biomarker for GH-axis peptides. CJC-1295 + Ipamorelin: IGF-1 typically rises 20-40% within 4-6 weeks of consistent dosing. Tesamorelin (FDA-approved GHRH analog): IGF-1 elevation documented in HIV-lipodystrophy trials. Sermorelin: similar but milder effect. BPC-157 / TB-500: no documented IGF-1 effect. Range above is for adult 30-49; falls naturally with age — older users should expect lower baseline.

Peptides that influence this marker

Documented to affect this marker. Click through for the full evidence-tiered profile.

• Tier 1 — Human RCTCJC-1295↑· by 8 weeks; stay within age-adjusted range — do not chase supraphysiologic
  GHRH analog

  GHRH analog — raises IGF-1 via pituitary GH pulse amplification

• Tier 1 — Human RCTCJC-1295 / Ipamorelin↑· by 8 weeks; target 30–80% rise from baseline, within age-adjusted range — do not chase supraphysiologic
  Blend

  Primary objective marker. IGFBP-3 as confirmatory.

• GHRP-2
  GH-releasing hexapeptide (GHRP)

  GHRP — raises IGF-1 via GH release; less selective than ipamorelin

• GHRP-6
  GH-releasing hexapeptide (ghrelin agonist)

  GHRP — raises IGF-1 via GH release; appetite stimulation common

• Hexarelin
  GH-releasing hexapeptide (GHRP)

  Strong GHRP — raises IGF-1; tachyphylaxis with continuous use

• IGF-1 LR3
  IGF-1 analog (extended half-life, reduced IGFBP binding)

  Direct exogenous IGF-1 analog — long half-life, displaces endogenous IGF-1 from binding proteins

• Tier 1 — Human RCTIpamorelin↑· by 8 weeks; stay within age-adjusted range — do not chase supraphysiologic
  GHRP / ghrelin mimetic

  GHRP — raises IGF-1 via ghrelin-receptor-mediated GH release

• MK-677 (Ibutamoren)
  Non-peptide ghrelin mimetic (small molecule)

  Oral GH secretagogue — sustained IGF-1 elevation; insulin sensitivity worth watching

• Tier 1 — Human RCTSermorelin↑· by 8 weeks; stay within age-adjusted range — do not chase supraphysiologic
  GHRH analog

  GHRH analog — modestly raises IGF-1 via endogenous GH

• Tier 1 — Human RCTTesamorelin↑· by 8 weeks; stay within age-adjusted range — do not chase supraphysiologic
  GHRH analog

  GHRH analog — raises IGF-1; FDA-approved for HIV-associated lipodystrophy

• Tier 1 — Human RCTTesamorelin / Ipamorelin↑· by 8 weeks; keep within age-adjusted range — do not chase supraphysiologic
  Blend

  Primary objective marker; the Ipamorelin layer amplifies the pulse but does not change the marker set.